Herceptin Label Should Add Abbott/Vysis’ PathVysion HER2 Assay – Cmte.
Executive Summary
Genentech's Herceptin (trastuzumab) labeling should add information about use of Vysis' PathVysion fluorescence in situ hybridization (FISH) test as an aid in selecting patients for therapy with the breast cancer drug, FDA's Oncologic Drugs Advisory Committee concluded Dec. 5